Week In Review: Abbisko Out-Licenses Rights To Precision NSCLC Medicine For $188 Million
March 04, 2023 at 14:20 PM EST
Abbisko Therapeutics out-licensed Greater China rights to a pre-clinical EGFR-TKI candidate for NSCLC to Allist Pharma in a $188 million deal. Also, Chipscreen Bio acquired greater China rights to a bispecific immunotherapy from Eucure Biopharma.
